[{"id":"ded56621-91d5-4fd3-83a0-0e173411e008","acronym":"","url":"https://clinicaltrials.gov/study/NCT05519397","created_at":"2022-08-29T13:03:09.156Z","updated_at":"2024-07-02T16:35:37.582Z","phase":"","brief_title":"Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy","source_id_and_acronym":"NCT05519397","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2023-09-11"},{"id":"4e0dcd1c-8c10-406d-8fe8-6a396d1d3f85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457075","created_at":"2022-07-13T11:56:50.702Z","updated_at":"2024-07-02T16:35:48.571Z","phase":"","brief_title":"Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer","source_id_and_acronym":"NCT05457075","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2023-05-09"},{"id":"d503b483-0df6-4db7-b6c7-c7c27120a653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05460702","created_at":"2022-07-15T16:05:37.936Z","updated_at":"2024-07-02T16:35:55.359Z","phase":"","brief_title":"Relationship Between Breast Cancer Subtypes and Immune Checkpoints","source_id_and_acronym":"NCT05460702","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2023-02-16"},{"id":"be7449e1-1a9b-46c1-af26-11ab58c0f0ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04540159","created_at":"2021-01-18T21:43:27.578Z","updated_at":"2024-07-02T16:35:59.572Z","phase":"","brief_title":"Immune Checkpoints in Intraabdominal Ascites Fluid","source_id_and_acronym":"NCT04540159","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-12-06"},{"id":"edbfae7e-f72f-4206-b13c-5cf6d41d84b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566848","created_at":"2021-01-18T21:48:53.808Z","updated_at":"2024-07-02T16:35:59.565Z","phase":"","brief_title":"The Status of Immune Checkpoints at Gastrointestinal Cancer","source_id_and_acronym":"NCT04566848","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2022-12-06"}]